In a similar fashion, treatment with trastuzumab or cetuximab prior to α4-1BB agonist therapy boosted ADCC and NK cell responses to HER2+ breast cancer or EGFR+ head and neck and colorectal carcinomas, respectively (143). Here, EGFR is linked to colorectal carcinoma.